Equities Analysts Offer Predictions for PRAX Q3 Earnings

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) – Equities research analysts at HC Wainwright boosted their Q3 2026 earnings estimates for Praxis Precision Medicines in a research note issued to investors on Friday, August 7th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of ($3.86) per share for the quarter, up from their prior forecast of ($3.87). HC Wainwright currently has a “Buy” rating and a $1,201.00 target price on the stock. The consensus estimate for Praxis Precision Medicines’ current full-year earnings is ($14.37) per share. HC Wainwright also issued estimates for Praxis Precision Medicines’ Q4 2026 earnings at ($4.15) EPS, FY2026 earnings at ($14.09) EPS, Q1 2027 earnings at ($2.98) EPS, Q2 2027 earnings at ($2.14) EPS, Q3 2027 earnings at ($0.72) EPS, Q4 2027 earnings at $1.38 EPS, FY2027 earnings at ($4.24) EPS, FY2028 earnings at $36.07 EPS, FY2029 earnings at $91.42 EPS and FY2030 earnings at $139.61 EPS.

A number of other research analysts have also recently weighed in on the stock. Wells Fargo & Company reissued a “positive” rating and set a $362.00 price objective (up from $323.00) on shares of Praxis Precision Medicines in a research note on Friday. TD Cowen reiterated a “buy” rating on shares of Praxis Precision Medicines in a report on Tuesday, June 2nd. Jefferies Financial Group reissued a “buy” rating on shares of Praxis Precision Medicines in a research report on Thursday, May 7th. Wedbush reduced their price objective on Praxis Precision Medicines from $166.00 to $162.00 and set an “underperform” rating on the stock in a research report on Tuesday, June 2nd. Finally, The Goldman Sachs Group started coverage on Praxis Precision Medicines in a research note on Monday, July 13th. They set a “buy” rating and a $447.00 price objective on the stock. Four research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Praxis Precision Medicines presently has an average rating of “Buy” and an average target price of $573.05.

Praxis Precision Medicines Price Performance

Shares of PRAX stock opened at $366.96 on Tuesday. The business’s fifty day moving average price is $304.62 and its 200 day moving average price is $316.08. The firm has a market capitalization of $10.25 billion, a PE ratio of -28.38 and a beta of 2.78. Praxis Precision Medicines has a 1-year low of $37.19 and a 1-year high of $382.54.

Praxis Precision Medicines (NASDAQ:PRAX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($2.87) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.67) by $0.80.

Institutional Trading of Praxis Precision Medicines

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Orbis Allan Gray Ltd purchased a new position in shares of Praxis Precision Medicines during the 4th quarter worth about $369,946,000. Janus Henderson Group PLC raised its stake in Praxis Precision Medicines by 17.2% during the fourth quarter. Janus Henderson Group PLC now owns 3,240,086 shares of the company’s stock worth $954,834,000 after purchasing an additional 476,227 shares during the period. Barclays PLC raised its stake in Praxis Precision Medicines by 592.6% during the fourth quarter. Barclays PLC now owns 530,751 shares of the company’s stock worth $156,434,000 after purchasing an additional 454,114 shares during the period. Baker BROS. Advisors LP boosted its holdings in shares of Praxis Precision Medicines by 63.4% in the 4th quarter. Baker BROS. Advisors LP now owns 1,126,488 shares of the company’s stock valued at $332,021,000 after purchasing an additional 437,000 shares during the last quarter. Finally, Perceptive Advisors LLC boosted its holdings in shares of Praxis Precision Medicines by 27.6% in the 4th quarter. Perceptive Advisors LLC now owns 1,995,986 shares of the company’s stock valued at $588,297,000 after purchasing an additional 431,432 shares during the last quarter. Hedge funds and other institutional investors own 67.84% of the company’s stock.

Insider Activity at Praxis Precision Medicines

In related news, Director Jill Desimone sold 11,600 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $311.32, for a total value of $3,611,312.00. Following the completion of the transaction, the director directly owned 2,337 shares in the company, valued at approximately $727,554.84. This represents a 83.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.00% of the stock is currently owned by corporate insiders.

Key Stories Impacting Praxis Precision Medicines

Here are the key news stories impacting Praxis Precision Medicines this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $14.09 from a loss of $14.49 and improved its FY2027 forecast to a loss of $4.24 from a loss of $5.33, indicating expectations for a faster path toward profitability.
• Positive Sentiment: The analyst significantly increased projected earnings for FY2028, FY2029 and FY2030 to $36.07, $91.42 and $139.61 per share, respectively. These estimates were raised from $29.24, $82.12 and $125.74, reinforcing the long-term commercial potential of Praxis’ pipeline.
• Positive Sentiment: The $1,201 target implies substantial upside from the stock’s recent trading level, while the continued Buy rating provides additional support for bullish investor sentiment.
• Neutral Sentiment: HC Wainwright projects continued losses through most of 2027, including EPS of negative $2.98 in the first quarter, negative $2.14 in the second quarter and negative $0.72 in the third quarter, before turning profitable with $1.38 EPS in the fourth quarter.
• Negative Sentiment: The firm reduced its Q4 2026 EPS estimate to a loss of $4.15 from a loss of $3.86. Although the Q3 2026 forecast improved slightly to a loss of $3.86 from a loss of $3.87, the revised near-term outlook still reflects significant operating losses.

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.